An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.
Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 25th largest by planned enrollment of the 118 observational ones that give a count, is one of 34 that started in 2026, is one of 118 observational ones, reaches primary completion later than 119 of the 124 other live ones, and was the 395th registered.
5,521 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 40–75
Tiantian Li · Sites in China
Ages 40–80
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
UCB Biopharma SRL · Sites in China, United States
Ages 40–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
404 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 42 · Phase 3 66 · Phase 4 33
First in 2000; this study’s year is marked. 34 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 155 across the 286 interventional studies, 500 across the 118 observational. Of the 183 that completed or were terminated, 47 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
160 of 404 have an industry lead sponsor. The 10 most frequent:
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 214 are open to participants now.
Nanfang Hospital, Southern Medical University has 3 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
29 of the studies in Pulmonary Disease, Chronic Obstructive with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT07658339Phase 3Haisco Pharmaceutical Group Co., Ltd.A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | 2027-06-11 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07583849Phase 3Haisco Pharmaceutical Group Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD | 2027-09-30 |
Add all 29 to your calendar (.ics) → With an account.
Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Approximately 100 million people in China have COPD, yet the early diagnosis rate remains below 13%. This multicenter retrospective study will collect previously acquired dynamic chest radiography (DCR) images, pulmonary function test results, chest computed tomography images, symptom scores, clinical data, and follow-up outcomes from participating centers. A standardized multicenter retrospective DCR-COPD database will be established to systematically evaluate the utility of DCR-derived parameters for characterizing dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of COPD progression. The study will also provide a foundation for model development and subsequent prospective multicenter validation.
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms, including dyspnea, cough, and sputum production. These symptoms result from airway abnormalities, such as bronchitis or bronchiolitis, and/or alveolar abnormalities, such as emphysema, that cause persistent and often progressive airflow obstruction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC \<0.7 after bronchodilator was used to confirm COPD.
After bronchial dilation, FEV1/FVC was ≥0.70, and FEV1%PRED was \<80%.
Smoking history of 10 years, or without COPD, pulmonary function of COPD diagnosis standard.
Never-smokers without airflow limitation and with normal pulmonary function.
Exacerbation/respiratory history and event
Measurement of disease control and burden
Time frame: At Baseline
FEV1 %
Measurement of lung function
Time frame: At Baseline
FEV1 /FVC
Measurement of lung function
Time frame: At Baseline
Emphysema
Measurement of chest CT
Time frame: At Baseline
diaphragm movement
Measurement of Dynamic chest radiograph
Time frame: At Baseline
lung field area
Measurement of Dynamic chest radiograph
Time frame: At Baseline
lung field area change rate
Measurement of Dynamic chest radiograph
Time frame: At Baseline
CAT
Measurement of questionnaires
Time frame: At Baseline
SGRQ
Measurement of questionnaires
Time frame: At Baseline
mMRC
Measurement of questionnaires
Time frame: At Baseline
Smoking history and status
Risk factors of COPD development or lung function decline
Time frame: At Baseline
Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Nanfang Hospital, Southern Medical University →